Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Finished Goods (2016 - 2026)

Amphastar Pharmaceuticals has reported Finished Goods over the past 11 years, most recently at $29.6 million for Q4 2025.

  • For Q4 2025, Finished Goods fell 24.87% year-over-year to $29.6 million; the TTM value through Dec 2025 reached $29.6 million, down 24.87%, while the annual FY2025 figure was $29.6 million, 24.87% down from the prior year.
  • Finished Goods for Q4 2025 was $29.6 million at Amphastar Pharmaceuticals, down from $37.7 million in the prior quarter.
  • Over five years, Finished Goods peaked at $41.6 million in Q2 2025 and troughed at $14.5 million in Q1 2022.
  • A 5-year average of $26.1 million and a median of $25.7 million in 2023 define the central range for Finished Goods.
  • Biggest five-year swings in Finished Goods: skyrocketed 91.35% in 2023 and later decreased 24.87% in 2025.
  • Year by year, Finished Goods stood at $17.7 million in 2021, then rose by 6.97% to $18.9 million in 2022, then soared by 31.99% to $24.9 million in 2023, then skyrocketed by 58.14% to $39.4 million in 2024, then decreased by 24.87% to $29.6 million in 2025.
  • Business Quant data shows Finished Goods for AMPH at $29.6 million in Q4 2025, $37.7 million in Q3 2025, and $41.6 million in Q2 2025.